Abstract:Failure of ductus arteriosus closure after preterm birth is associated with significant morbidities. Ductal closure requires and is regulated by a complex interplay of molecular and mechanical mechanisms with underlying genetic factors. <i>In utero</i> patency of the ductus is maintained by low oxygen tension, high levels of prostaglandins, nitric oxide and carbon monoxide. After birth, ductal closure occurs first by functional closure, followed by anatomical remodeling. High oxygen tension and decreased prostaglandin levels mediated by numerous factors including potassium channels, endothelin-1, isoprostanes lead to the contraction of the ductus. Bradykinin and corticosteroids also induce ductal constriction by attenuating the sensitivity of the ductus to PGE2. Smooth muscle cells of the ductus can sense oxygen through a mitochondrial network by the role of Rho-kinase pathway which ends up with increased intracellular calcium levels and contraction of myosin light chains. Anatomical closure of the ductus is also complex with various mechanisms such as migration and proliferation of smooth muscle cells, extracellular matrix production, endothelial cell proliferation which mediate cushion formation with the interaction of blood cells. Regulation of vessel walls is affected by retinoic acid, TGF-β1, notch signaling, hyaluronan, fibronectin, chondroitin sulfate, elastin, and vascular endothelial cell growth factor (VEGF). Formation of the platelet plug facilitates luminal remodeling by the obstruction of the constricted ductal lumen. Vasa vasorum are more pronounced in the term ductus but are less active in the preterm ductus. More than 100 genes are effective in the prostaglandin pathway or in vascular smooth muscle development and structure may affect the patency of ductus. Hemodynamic changes after birth including fluid load and flow characteristics as well as shear forces within the ductus also stimulate closure. Current pharmacological treatment for the closure of a patent ductus is based on the blockage of the prostaglandin pathway mainly through COX or POX inhibition, albeit with some limitations and side effects. Further research for new agents aiming ductal closure should focus on a clear understanding of vascular biology of the ductus.

Vav2 Promotes Ductus Arteriosus Anatomic Closure Via the Remodeling of Smooth Muscle Cells by Rac1 Activation

[Factors Influencing the Prognosis of Patent Ductus Arteriosus in Very Low Birth Weight Infants].

Gamma-secretase Inhibitor Prevents Proliferation and Migration of Ductus Arteriosus Smooth Muscle Cells through the Notch3-HES1/2/5 Pathway

Identification and Functional Verification of CITED2 Gene Promoter Region in Patients with Patent Ductus Arteriosus.

Tfap2b Mutation in Mice Results in Patent Ductus Arteriosus and Renal Malformation.

A Novel Gata4 Mutation Responsible for Congenital Ventricular Septal Defects

Role of Prostaglandin E2 and Its Receptors in the Process of Ductus Arteriosus Maturation and Functional Closure in the Rabbit

Altered Plasma Proteins Released From Platelets And Endothelial Cells Are Associated With Human Patent Ductus Arteriosus

A Novel NKX2-5 Mutation in Familial Ventricular Septal Defect.

Patent Ductus Arteriosus Closure Using the New Amplatzer Duct Occluder. Preliminary Results and Review of the Literature.

[Mutation of TFAP-2B Gene in Patients with Patent Ductus Arteriosus].

Next Generation Sequencing Identify Rare Copy Number Variants in Non-syndromic Patent Ductus Arteriosus

Cinaciguat Prevents Postnatal Closure of Ductus Arteriosus by Vasodilation and Anti-remodeling in Neonatal Rats

The Role of Na+/Ca2+Exchanger 1 in Maintaining Ductus Arteriosus Patency

Variants of the promoter of MYH6 gene in congenital isolated and sporadic patent ductus arteriosus: case-control study and cellular functional analyses

Characterization of transcription factor AP-2 beta mutations involved in familial isolated patent ductus arteriosus suggests haploinsufficiency

Exendin-4, a glucagon-like peptide-1 receptor agonist, regulates ductus arteriosus by vasodilation and anti-remodeling through the PKA pathway

Association of patent ductus arteriosus with fetal factors and endotypes of prematurity

Elevated NCX1 and NCKX4 Expression in the Patent Postnatal Ductus Arteriosus of Ductal-Dependent Congenital Heart Disease Patients

Loss of Notch2 and Notch3 in vascular smooth muscle causes patent ductus arteriosus

Molecular and Mechanical Mechanisms Regulating Ductus Arteriosus Closure in Preterm Infants